lethally irradiated mice [3] . In cultures of bone marrow cells from untreated patients with chronic granulocytic leukaemia (CML), the Philadelphia chromosome decreased, after being present in over 95% of mitoses, to almost undetectable levels. In the same cultures, Ph-negative cells became the predominant mitotic population [4] . Similarly, in some cultures established from bone marrow from patients with newly diagnosed acute myeloblastic leukaemia (AML) , the size of the leukaemic clone (assessed either by chromosome markers or by a characteristic abnormal growth pattern in colony assays) diminished to undetectable levels, while normal haemopoiesis became dominant ( [5, 6] and our unpublished results). A similar pattern may also be seen in cultures established from bone marrow in relapse.
From these experimental data, summarized in Table 1 , it would appear that the conditions prevailing in vitro may both suppress the growth of leukaemic cells and fa- [3] [4] [5, 6] cilitate the regeneration of normal haemopoietic cells from the small numbers of normal progenitors still present in the leukaemic marrows. These observations led us to perform autologous bone marrow transplants (BMT), using cultured cells, in AML patients who were thought to be able to benefit from bone marrow transplantation and who had no HLA-matched donors.
B. Methods
Patient details are shown in Table 3 . All patients had received three courses of combination chemotherapy, each consisting of a 7-day infusion of cytosine arabinoside, oral thioguanine and three injections of daunorubicin. Time elapsed from end of chemotherapy to bone marrow harvest is shown. Two patients were harvested early in first relapse without having received additional chemotherapy. Marrow was harvested under general anaesthetic and used to establish long-term cultures (Fig. 1) . The protocol followed in the BMT is shown in Table 2 . The patients were nursed in a laminar-flow tent, received prophylactic oral antimicrobials and a low-pathogen diet, prophylactic transfusions of irradiated platelets and irra- 
c. Results
Details of BMT, haematological recovery and outcome are shown in Tables 3 and 4 . The first patient was in early relapse at the time of marrow harvest. Serial cytogenetic studies performed during the preceding clinical remission had shown that the 16q abnormality which characterised his leukaemic clone had persisted in about onefifth of the mitoses from the bone marrow. However, only normal mitoses were detected after the bone marrow had been in culture for 7-14 days [6] . Following transplantation, full reconstitution was achieved, the 16q marker became undetectable (for the first time since diagnosis) and the patient entered a full remission. The second patient transplanted in relapse (without a chromosomal marker) regenerated leukaemia 12 weeks after BMT. He continue sin good clinical condition, leading an active life on haematological support. One patient transplanted in remission following chemotherapy for transformation of a myelodysplastic syndrome reverted not to normal haemopoiesis, but to myelodysplasia after the transplant. She required support transfusions until she died. Two patients transplanted in first remission are in complete remission after 58 and 30 weeks, respectively. 
D. Discussion
The haematological recovery and lack of procedural mortality in the five patients transplanted strongly suggest that the cultured cells engrafted and that this technique can be reliably used for autologous BMT. The recovery of peripheral blood cells, and especially of platelets, was slower than after allogeneic transplantation, but prolonged thrombocytopenia has been observed after conventional autologous transplantation [7] . In this context, as one of the patients in this series shows, a history of myelodysplasia may be a contraindication for autologous transplant.
The altered balance between the leukaemic and normal populations in culture is likely to be responsible for the remission achieved in the first patient. However, the high leukaemic load existing in the patient at the time of the ablative therapy, prior to transplantation, made the eventual relapse not unexpected. It is probable that relapses after autologous and allogeneic BMT are usually due to leukaemic cells which remain in the host after the conditioning treatment preceding the transplant. Because of this, relapses are to be expected with the present conditioning regimes in at least 25% of patients transplanted in first remission of AML.
The results, although preliminary, are encouraging and allow us to consider the possibility of manipulating the cultures by regulatory molecules (colony-stimulating factors, interferons and others) which may induce differentiation of leukaemic cells [8] and favour the growth of normal haemopoietic progenitors. Experiments along these lines are in progress. In addition, the use of cultured bone marrow for autologous transplants in CML, poor-prognosis acute lymphoblastic leukaemia or in some patients with solid tumors are possible developments for the future.
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